David A Lipson

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 27

Top Topics

Chronic Obstructive Pulmonary Disease

General Practice

Top Venues

International journal of chronic obstructive pulmonary disease

American journal of respiratory and critical care medicine

The European respiratory journal

This page only lists publications with an associated author ORCID identifier.

Publications

Edward M Kerwin, Paul W Jones, Leif H Bjermer, François Maltais, Isabelle H Boucot, Ian P Naya, David A Lipson, Chris Compton, Lee Tombs, Claus F Vogelmeier
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting? Chronic respiratory disease 20 (2023)
Mark T Dransfield, Gerard J Criner, David M G Halpin, MeiLan K Han, Benjamin Hartley, Ravi Kalhan, Peter Lange, David A Lipson, Fernando J Martinez, Dawn Midwinter, Dave Singh, Robert Wise, Ken M Kunisaki
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial. Journal of the American Heart Association 11 (18) (2022)
Reynold A Panettieri, Carlos Arturo Camargo, Tariq Cheema, Sherif G El Bayadi, Stanley Fiel, Tania M Vila, Renu G Jain, Dawn Midwinter, Byron Thomashow, Andrea Ludwig-Sengpiel, David A Lipson
Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Peter M A Calverley, Fernando J Martinez, Jorgen Vestbo, Christine R Jenkins, Robert A Wise, David A Lipson, Nicholas J Cowans, Julie Yates, Courtney Crim, Bartolome R Celli
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. American journal of respiratory and critical care medicine 206 (1) (2022)
Leah B Sansbury, David A Lipson, Chanchal Bains, Glenn A Anley, Kieran J Rothnie, Afisi S Ismaila
Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. International journal of chronic obstructive pulmonary disease 17 (2022)
Philip J Thompson, Gerard J Criner, Mark T Dransfield, David M G Halpin, MeiLan K Han, David A Lipson, Ghassan J Maghzal, Fernando J Martinez, Dawn Midwinter, Dave Singh, Lee Tombs, Robert A Wise
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial. Respirology (Carlton, Vic.) 27 (12) (2022)
Andrea Gabrio, Necdet B Gunsoy, Gianluca Baio, Alan A Martin, Victoria Federico Paly, Nancy Risebrough, David M G Halpin, Dave Singh, Robert A Wise, MeiLan K Han, Fernando J Martinez, Gerard J Criner, Neil Martin, David A Lipson, Afisi S Ismaila
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Sandeep Bansal, Martin Anderson, Antonio Anzueto, Nicola Brown, Chris Compton, Thomas C Corbridge, David Erb, Catherine Harvey, Morrys C Kaisermann, Mitchell Kaye, David A Lipson, Neil Martin, Chang-Qing Zhu, Alberto Papi
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. NPJ primary care respiratory medicine 31 (1) (2021)
Bjermer Leif, Isabelle H Boucot, Claus F Vogelmeier, Francois Maltais, Paul W Jones, Lee Tombs, Chris Compton, David A Lipson, Edward M Kerwin
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in therapy 38 (9) (2021)
Leah B Sansbury, Chanchal Bains, David A Lipson, Afisi S Ismaila, Sarah H Landis
Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. International journal of chronic obstructive pulmonary disease 16 (2021)
Claus F Vogelmeier, Ian P Naya, Francois Maltais, Bjermer Leif, Edward M Kerwin, Lee Tombs, Paul W Jones, Chris Compton, David A Lipson, Isabelle H Boucot
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. International journal of chronic obstructive pulmonary disease 16 (2021)
Bjermer Leif, Isabelle H Boucot, Francois Maltais, Edward M Kerwin, Ian P Naya, Lee Tombs, Paul W Jones, Chris Compton, David A Lipson, Claus F Vogelmeier
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International journal of chronic obstructive pulmonary disease 16 (2021)
David A Lipson, MeiLan K Han, Robert A Wise, Fernando J Martinez
Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. American journal of respiratory and critical care medicine 203 (7) (2021)
Neil C Barnes, Dave Singh, David A Lipson
Reply to: "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Letter]. International journal of chronic obstructive pulmonary disease 16 (2021)
Soham Shukla, Dhvani Shah, Alan A Martin, Nancy A Risebrough, Robyn Kendall, Claus F Vogelmeier, Isabelle H Boucot, Lee Tombs, Bjermer Leif, Paul W Jones, Edward M Kerwin, Chris Compton, Francois Maltais, David A Lipson, Afisi S Ismaila
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International journal of chronic obstructive pulmonary disease 16 (2021)
Mona Bafadhel, Neil Barnes, Stephen C Bourke, Chris Compton, Gerard J Criner, Mark T Dransfield, David M G Halpin, MeiLan K Han, Benjamin Hartley, C Elaine Jones, Peter Lange, Sally Lettis, David A Lipson, David A Lomas, Neil Martin, Fernando J Martinez, Robert A Wise, Dave Singh
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. The European respiratory journal 58 (3) (2021)
Rashmi Mehta, Colm Farrell, Siobhán Hayes, Ruby Birk, Malek Okour, David A Lipson
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Clinical pharmacokinetics 59 (1) (2021)
MeiLan K Han, Gerard J Criner, Mark T Dransfield, David M G Halpin, Christine E Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A Lipson, David A Lomas, Neil Martin, Fernando J Martinez, Robert A Wise, Ian P Naya, Dave Singh
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ open research 7 (1) (2021)
Robert A Wise, Mona Bafadhel, Courtney Crim, Gerard J Criner, Nicola C Day, David M G Halpin, MeiLan K Han, Peter Lange, David A Lipson, Fernando J Martinez, Diego Jose Maselli, Dawn Midwinter, Dave Singh, Maeva Zysman, Mark T Dransfield, Richard E K Russell
Discordant diagnostic criteria for pneumonia in COPD trials: a review. European respiratory review : an official journal of the European Respiratory Society 30 (162) (2021)
Jean Bourbeau, Mona Bafadhel, Neil C Barnes, Chris Compton, Valentina Di Boscio, David A Lipson, Paul W Jones, Neil Martin, Gudrun Weiss, David M G Halpin
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. International journal of chronic obstructive pulmonary disease 16 (2021)
David A Lipson, Courtney Crim, Gerard J Criner, Nicola C Day, Mark T Dransfield, David M G Halpin, MeiLan K Han, C Elaine Jones, Sally Kilbride, Peter Lange, David A Lomas, Sally Lettis, Pamela Manchester, Neil Martin, Dawn Midwinter, Andrea Morris, Steven J Pascoe, Dave Singh, Robert A Wise, Fernando J Martinez
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine 201 (12) (2020)
David M G Halpin, Mark T Dransfield, MeiLan K Han, C Elaine Jones, Sally Kilbride, Peter Lange, David A Lipson, David A Lomas, Fernando J Martinez, Steve Pascoe, Dave Singh, Robert A Wise, Gerard J Criner
The effect of exacerbation history on outcomes in the IMPACT trial. The European respiratory journal 55 (5) (2020)
Nanshan Zhong, Jin-Ping Zheng, Sang Haak Lee, David A Lipson, Xin Du, Shunquan Wu
Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study. International journal of chronic obstructive pulmonary disease 15 (2020)
David A Lipson, Mark T Dransfield, MeiLan K Han
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma? American journal of respiratory and critical care medicine 202 (5) (2020)
Benjamin Hartley, Gerard J Criner, Mark T Dransfield, David M G Halpin, MeiLan K Han, C Elaine Jones, Sally Kilbride, Peter Lange, David A Lipson, David A Lomas, Neil Martin, Fernando J Martinez, Dave Singh, Robert A Wise, Sally Lettis
Misinterpretation of time-to-first event curves can lead to inappropriate treatment. The European respiratory journal 54 (3) (2019)
Motokazu Kato, Keisuke Tomii, Kenichi Hashimoto, Yasuko Nezu, Takeo Ishii, C Elaine Jones, Sally Kilbride, Annette S Gross, Christine S Clifton, David A Lipson
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population. International journal of chronic obstructive pulmonary disease 14 (2019)
Riju Ray, Lee Tombs, Michael J Asmus, Isabelle H Boucot, David A Lipson, Chris Compton, Ian Naya
Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials. Drugs & aging 35 (7) (2018)